Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 706 plus paclitaxel in HER2-negative locally recurrent or metastatic breast cancer
ACTRN12606000507583Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of motesanib in breast cancer, sponsored by Amgen. Primary endpoint: Objective response rate. Started Sep 2007; status: completed.
02
Drugs
motesanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000507583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000507583.